NeuroStar® Launches Better Me Provider Program Nationwide
01 7월 2024 - 9:02PM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced the national launch of the Better
Me Provider (BMP) program, pioneering new standards in patient care
and responsiveness to improve treatment accessibility within the
mental health industry. The providers participating in the program
are committed to rigorous standards, developed in collaboration
with a network of TMS medical experts.
“The Better Me Provider Program is an approach that considers
the entire patient journey, providing an optimal experience to get
the help they need faster,” stated Keith J. Sullivan, President and
CEO of Neuronetics, Inc. “We are excited for more NeuroStar
providers to participate in the program and continue to make our
life-changing treatment more accessible to the 29 million people
suffering from MDD, OCD, and anxious depression.”
During the pilot phase, the BMP program demonstrated remarkable
success by significantly enhancing provider efficiency and
responsiveness, thus improving the experience for NeuroStar
patients.
- Improved response times: Participating
practices raised the bar for response times, achieving up to a 6.4x
improvement in 24-hour follow-ups compared to non-BMP
providers.
- Advanced training: Through advanced clinical
training at NeuroStar University (NSU), participants learned the
latest techniques for building patient awareness and treating
patients with NeuroStar, allowing these attendees to treat 58% more
patients on average than their non-attendee counterparts, ensuring
that more patients in need receive potentially life-changing
therapy.
- Swiftly addressed interested patients: The
program also significantly accelerated patient engagement, reducing
the time from initial interest to motor threshold (MT)
determination fivefold compared to the previous year. This led to
3.6x more MT determinations, which has the potential to transform
more patients' lives.
“Being part of the Better Me Provider program means not only
upholding proven standards but also contributing to a collective
effort to address the pressing mental health challenges our society
faces,” said Dr. Melissa Fickey, Founder of Embracing Life Wellness
Center.
The BMP program, a comprehensive commercial initiative, is
nationally available today where NeuroStar Practice Development
Managers will continue to collaborate with NeuroStar practices to
help them meet the qualifying criteria and enroll in the program.
There are currently 300 active sites in the program, with over 125
more committed to adhering to the standards in anticipation of the
national rollout in July. For more information about NeuroStar TMS
Therapy, please visit www.neurostar.com.
About the NeuroStar Better Me Provider
ProgramBetter Me Provider Program is a comprehensive
commercial initiative to support practices committed to rigorous
standards, developed in collaboration with a network of TMS medical
experts. The Better Me Providers are practices committed to meeting
the following patient care and responsiveness standards, developed
in collaboration with medical experts: performing TMS therapy
exclusively with NeuroStar, attending NeuroStar University;
ensuring prompt response times by a dedicated NeuroStar
coordinator; advising patients about the benefits of a full course
of NeuroStar treatment; and optimizing websites and social media
content to educate patients.
This material is for informational purposes only and is not
intended to constitute clinical advice. Neuronetics, Inc. is not a
medical provider, does not provide medical or clinical advice, and
does not recommend or endorse any medical provider or specific
health care service through the Better Me Provider Program. This
material is not a substitute for professional medical advice,
diagnosis, or treatment. If you are having an emergency, please
call 911, or if you are having a mental health emergency, please
call 988 or 800-273-8255. Always seek the advice of your physician
or other qualified health care provider with any questions you may
have regarding a medical condition or treatment and before
undertaking a new health care regimen, and never disregard
professional medical advice or delay in seeking it because of this
content.
Clinical evidence demonstrates superior outcomes for patients
who complete a course of NeuroStar therapy compared to those who do
not complete treatment. However, the actual number of sessions
performed is subject to the medical judgment of the prescribing
provider. The number of treatment sessions performed is not a
selection criterion for entry into the Better Me Provider Program
and will not be used as a basis to remove a provider from the
Better Me Provider Program.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is indicated for the treatment of depressive episodes and
for decreasing anxiety symptoms for those who may exhibit comorbid
anxiety symptoms in adult patients suffering from MDD and who
failed to achieve satisfactory improvement from previous
antidepressant medication treatment in the current episode. It is
also FDA-cleared as an adjunct for adults with obsessive-compulsive
disorder and for adolescent patients aged 15-21 with MDD. NeuroStar
Advanced Therapy is the leading TMS treatment for MDD in adults
with over 6.4 million treatments delivered. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing information,
visit www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Neuronetics (NASDAQ:STIM)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024